Amylyx Pharmaceuticals, Inc.
AMLX
Peringkat dalam Saham
#4526
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$27.08
Kapitalisasi Pasar
$3.40B
Perubahan (1 hari)
2.82%
Perubahan (1 tahun)
81.16%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
EPS untuk Amylyx Pharmaceuticals, Inc. (AMLX)
EPS per June 2026 TTM: $-1.41
Menurut laporan keuangan terbaru dan harga saham Amylyx Pharmaceuticals, Inc., EPS perusahaan saat ini (TTM) adalah $-1.41. Pada akhir 2023, perusahaan memiliki EPS sebesar $0.73 peningkatan dibandingkan EPS tahun 2022 sebesar $-2.98.
Riwayat EPS untuk Amylyx Pharmaceuticals, Inc. dari 2019 hingga 2026
EPS di akhir setiap tahun
| Tahun | EPS | Mengubah |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS untuk perusahaan sejenis atau pesaing
| Perusahaan | EPS | Perbedaan EPS | Negara |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
